Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial by Smith, Matthew R, Prof, Scher, Howard I, Prof, Sandhu, Shahneen, MD, Efstathiou, Eleni, MD, Lara, Primo N, Prof, Yu, Evan Y, Prof, George, Daniel J, Prof, Chi, Kim N, Prof, Saad, Fred, Prof, Ståhl, Olof, MD, Olmos, David, MD, Danila, Daniel C, MD, Mason, Gary E, MD, Espina, Byron M, BS, Zhao, Xin, PhD, Urtishak, Karen A, PhD, Francis, Peter, MD, Lopez-Gitlitz, Angela, MD, Fizazi, Karim, Prof

Get full text